Durable Response to Enfortumab Vedotin Compared to Re-challenging Chemotherapy in Metastatic Urothelial Carcinoma After Checkpoint Inhibitors.

Kazumasa KomuraShuya TsuchidaKazumasa KomuraWataru FukuokayaTakahiro AdachiYosuke HirasawaTakeshi HashimotoAtsuhiko YoshizawaMasanobu SarutaMamoru HashimotoTakuya HigashioTakuya MatsudaKazuki NishimuraTakuya TsujinoKo NakamuraTatsuo FukushimaKyosuke NishioShutaro YamamotoKosuke IwataniFumihiko UrabeKeiichiro MoriTakafumi YanagisawaShunsuke TsudukiKiyoshi TakaharaTeruo InamotoJun MikiKazutoshi FujitaTakahiro KimuraYoshio OhnoRyoichi ShirokiHirotsugu UemuraHaruhito Azuma

Published in: Targeted oncology (2024)

A superior effect of EV on patient survival compared to re-challenging chemotherapy and continuing pembrolizumab beyond PD was observed in our real-world analysis, which is attributed to the durable DOR in EV treatment despite the similar ORR to re-challenging chemotherapy.

Keyphrases

locally advanced
squamous cell carcinoma
small cell lung cancer
dna damage
case report
cell cycle
rectal cancer
chemotherapy induced
radiation therapy
advanced non small cell lung cancer
hodgkin lymphoma
free survival
tyrosine kinase
data analysis